Company Filing History:
Years Active: 2018
Title: Jacques Moisan: Innovator in Immunotherapy
Introduction
Jacques Moisan is a prominent inventor based in North Potomac, MD (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative work on CTLA-4 variants. His research focuses on enhancing the efficacy and stability of treatments for autoimmune diseases.
Latest Patents
Jacques Moisan holds a patent for CTLA-4 variants, which are designed to have high affinity, potency, and stability. This patent includes formulations of CTLA-4 variants that can be administered at high concentrations via subcutaneous or intravenous routes, allowing for less frequent dosage intervals, such as monthly. The use of these variants is particularly aimed at treating rheumatoid arthritis and other inflammatory disorders. Additionally, his work involves the fusion of CTLA-4 with IgG Fc, which improves stability and extends the in vivo half-life of the treatment.
Career Highlights
Jacques Moisan is associated with Medimmune Limited, where he continues to advance his research in immunotherapy. His work has the potential to significantly impact the treatment landscape for various inflammatory conditions.
Collaborations
Jacques has collaborated with notable colleagues, including Ralph Raymond Minter and Julie Ann Douthwaite, contributing to a dynamic research environment that fosters innovation.
Conclusion
Jacques Moisan's contributions to the field of immunotherapy through his patented CTLA-4 variants exemplify the importance of innovation in medical science. His work not only enhances treatment options for patients but also showcases the potential of targeted therapies in managing autoimmune diseases.